LEADER 02742nam 22004815 450 001 9910253946903321 005 20200704095932.0 010 $a3-319-70142-8 024 7 $a10.1007/978-3-319-70142-4 035 $a(CKB)4100000001382021 035 $a(DE-He213)978-3-319-70142-4 035 $a(MiAaPQ)EBC5182420 035 $a(PPN)222229233 035 $a(EXLCZ)994100000001382021 100 $a20171204d2017 u| 0 101 0 $aeng 135 $aurnn|008mamaa 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aResistance to Targeted Therapies in Breast Cancer /$fedited by Jenifer R. Prosperi 205 $a1st ed. 2017. 210 1$aCham :$cSpringer International Publishing :$cImprint: Springer,$d2017. 215 $a1 online resource (XV, 184 p. 12 illus. in color.) 225 1 $aResistance to Targeted Anti-Cancer Therapeutics,$x2196-5501 ;$v16 311 $a3-319-70141-X 320 $aIncludes bibliographical references at the end of each chapters and index. 327 $aInvasive Breast Cancer Therapy 2017: How Well Are We Hitting The Target? -- Resistance to HER2-targeted therapy -- Endocrine Resistance and Breast Cancer Stem Cells ? The Inflammatory Connection That Could Lead to New and Improved Therapy Outcomes -- EGFR Resistance -- Targeting FGFR for the treatment of breast cancer -- Targeted Therapies in Breast Cancer -- Future paradigm of breast cancer resistance and treatment. 330 $aWe present an in-depth description of resistance to targeted therapies in breast cancer. Targeted therapies discussed here include those used to treat ER+ or Her2+ breast cancers (i.e., Tamoxifen or trastuzumab) or those targeting signaling pathways aberrantly activated in triple negative breast cancer (i.e., EGFR and Wnt signaling). We have also provided an overview of standard of care as an introduction into the importance of targeted therapy. It is our hope that this volume gives an insight into the landscape of breast cancer treatment, the challenges of targeted therapy, and a glimpse into the future of breast cancer therapy.  . 410 0$aResistance to Targeted Anti-Cancer Therapeutics,$x2196-5501 ;$v16 606 $aCancer research 606 $aCancer Research$3https://scigraph.springernature.com/ontologies/product-market-codes/B11001 615 0$aCancer research. 615 14$aCancer Research. 676 $a616.99449061 702 $aProsperi$b Jenifer R$4edt$4http://id.loc.gov/vocabulary/relators/edt 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910253946903321 996 $aResistance to Targeted Therapies in Breast Cancer$92019300 997 $aUNINA